Genmab
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Genmab sits in the top decile of US sponsors by registered trial count (#397 of 15,742 sponsors by registered trial count).
Genmab: 45 sponsored US clinical trials, 11 recruiting.
Genmab sponsors 45 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 4 completed. 10 of these trials are in Phase 3-4 (later-stage) and 35 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Diffuse Large B Cell Lymphoma, with 6 trials.
Top-decile sponsor footprint
Genmab ranks in the top decile of sponsors by registered trial count (#397 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
4 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (25.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
45 total, page 1 of 1
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers
NCT07539311
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy
NCT07225270
A Study of GEN1106 in Participants With Solid Tumors
NCT07416123
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
NCT07387068
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
NCT07288177
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
NCT06573294
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
NCT06191744
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05283720
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
NCT06984328
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
NCT06635824
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
NCT06685068
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
NCT05660967
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
NCT05578976
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
NCT05206357
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
NCT05409066
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
NCT05451810
GEN1047 for Solid Tumors - First in Human (FIH) Trial
NCT05180474
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
NCT05117242
A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
NCT04628494
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
NCT04623541
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
NCT04663347
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599
GEN1046 Safety Trial in Patients With Malignant Solid Tumors
NCT03917381
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer
NCT07564141
Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
NCT06391775
PRO1107 in Patients With Advanced Solid Tumors
NCT06171789
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
NCT06018129
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
NCT05721222
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
NCT05435339
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
NCT04824794
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
NCT04424641
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
NCT04358458
GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
NCT03576131
Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
NCT02988817
Zalutumumab in Non-curable Patients With SCCHN
NCT00542308
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
NCT00460551
Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer
NCT00401401
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
NCT00071084
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
NCT00071071
Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Treatment With Methotrexate (MTX) and a TNF-alpha Blocker
NCT00042406
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 23 |
| Phase 2 | 12 |
| Phase 3 | 10 |
Therapeutic Areas
What is open in the Genmab pipeline
11 recruiting of 45 indexed (24% open); 4 completed (9%).
Phase mix: 10 late (III/IV) vs 35 early (I/II) (early-phase heavy).
Top condition: Diffuse Large B Cell Lymphoma (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Genmab: open-pipeline peers nationwide
Peers matched on 45 registered trials and 24% open enrollment, not the therapeutic-area sidebar.
Genmab sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 45 trials (± recruiting share)
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 45 trials · 4% recruiting
- AIDS Malignancy Consortium · 45 trials · 11% recruiting
- Cambridge Health Alliance · 45 trials · 16% recruiting
- Carilion Clinic · 45 trials · 20% recruiting
Sponsors near 24% open enrollment (± trial volume)
- Center for International Blood and Marrow Transplant Research · 24% recruiting · 29 trials
- AdventHealth Translational Research Institute · 24% recruiting · 54 trials
- Auburn University · 24% recruiting · 54 trials
- AB Science · 25% recruiting · 8 trials
Related
What to do with this Genmab page
45 registered trials is a research-attention snapshot, not an endorsement of Genmab or any single study.
- 11 of Genmab's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Diffuse Large B Cell Lymphoma is the condition Genmab studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diffuse Large B Cell Lymphoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Genmab pipeline card: 45 registered trials from official public datasets.Report a data error.